iRhythm Technologies

IRTC

Market cap $5.66B

Overview Fund Activity

176.16 USD

-3.66

2.04%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

176.16

0.00

0%

1 day

-2.04%

5 days

-5.59%

1 month

9.7%

3 months

21.65%

6 months

69.87%

Year to date

96.96%

1 year

139.02%

5 years

-22.15%

10 years

576.24%

About: iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Employees: 2,000

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

214% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 22

67% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 5 (+2) [Q2]

44% more capital invested

Capital invested by funds: $3.77B [Q1] → $5.44B (+$1.67B) [Q2]

18% more funds holding

Funds holding: 255 [Q1] → 300 (+45) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 93

3.7% less ownership

Funds ownership: 114.56% [Q1] → 110.86% (-3.7%) [Q2]

28% less call options, than puts

Call options by funds: $27.3M | Put options by funds: $37.6M

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$147

17% downside

Avg. target

$180

2% upside

High target

$200

14% upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Needham David Saxon	$193	Buy Maintained	28 Aug 2025
Citigroup Joanne Wuensch	$183	Buy Maintained	21 Aug 2025
B of A Securities Stephanie Piazzola	$200	Buy Initiated	20 Aug 2025
JP Morgan Allen Gong	$190	Overweight Maintained	1 Aug 2025
Canaccord Genuity William Plovanic	$170	Buy Maintained	1 Aug 2025
Wells Fargo Nathan Treybeck	$180	Overweight Maintained	1 Aug 2025
Morgan Stanley Cecilia Furlong	$147	Overweight Maintained	15 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about IRTC published over the past 30 days

IRhythm Technologies, Inc. (IRTC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Quentin Blackford - President, CEO & Director Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Okay. Welcome. Thanks for everyone joining day 2 of BMS Global Healthcare Conference.

IRhythm Technologies, Inc. (IRTC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zacks Investment Research

IRTC Unveils Positive AMALFI Trial Data Showing Higher AF Detection

iRhythm's AMALFI trial shows its Zio monitoring service boosts AF detection and speeds diagnosis, strengthening its edge in cardiac care.

IRTC Unveils Positive AMALFI Trial Data Showing Higher AF Detection

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies' Zio LTCM Service

SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced results from the Oxford University-led A ctive M onitoring for A tria L FI brillation (AMALFI) randomized clinical trial, presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the Journal of the American Medical Association (JAMA) , demonstrating that home-based screening with the Zio® long-term continuous monitoring (LTCM) service led to increased atrial fibrillation (AFib) detection and a shorter time to diagnosis.

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies' Zio LTCM Service

iRhythm Technologies to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences.

iRhythm Technologies to Participate in Upcoming Investor Conferences

Investor Short Report Flags Steep Downside Risk For iRhythm Technologies

Spruce Point Capital Management issued a detailed report on iRhythm Technologies, Inc. IRTC on Monday, projecting a long-term downside risk of 40% to 70% for its stock.

Investor Short Report Flags Steep Downside Risk For iRhythm Technologies

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries (AVALON) in the American Journal of Managed Care reinforcing the clinical superiority of the Zio® long-term continuous monitoring (LTCM) service.

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority

The Motley Fool

iRhythm (IRTC) Q2 Revenue Jumps 26%

iRhythm Technologies (IRTC 17.81%), a medical device company specializing in cardiac monitoring technology, reported its Q2 FY2025 results on July 31, 2025. The highlight was record revenue (GAAP) of $186.7 million, up 26.1% from the previous year and beating analyst expectations by $12.7 million.

iRhythm (IRTC) Q2 Revenue Jumps 26%

iRhythm Technologies, Inc. (IRTC) Q2 2025 Earnings Call Transcript

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Daniel G. Wilson - CFO & Principal Financial Officer Quentin S.

iRhythm Technologies, Inc. (IRTC) Q2 2025 Earnings Call Transcript

Zacks Investment Research

iRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

iRhythm Technologies (IRTC) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.61 per share a year ago.

iRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

iRhythm Technologies Announces Second Quarter 2025 Financial Results

SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024 Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024 Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025 Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights Second quarter 2025 record quarterly revenue driven by continued momentum in our core long-term continuous monitoring business, sustained demand for Zio AT, progress within innovative value-based care accounts, and contribution from international markets Executed strategic partnership with Lucem Health, a leader in AI-driven early disease detection, to accelerate early identification of undiagnosed arrhythmias in patient populations with comorbid conditions, a bold step toward predictive, preventive, and precise care that is powered by AI, informed by data, and designed for scale1 Results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025) demonstrated that cardiac arrhythmias present frequent, early, and often preceding major cardiovascular events (MACE), highlighting a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations "The second quarter of 2025 was another record quarter for iRhythm, with growth of more than 26%, showcasing the strength of our diversified growth strategy," said Quentin Blackford, President and Chief Executive Officer of iRhythm.

iRhythm Technologies Announces Second Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™